文献速递冠心病

替格瑞洛与普拉格雷对ST段抬高型心肌梗死血运重建后微血管损伤的影响

Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel.
PubMed 文献 · Circulation · 2019-01-01

本研究将110例接受直接PCI的STEMI患者随机分为替格瑞洛(n=56)或普拉格雷(n=54)维持治疗,主要终点为1个月时梗死相关动脉的微循环阻力指数(IMR)。结果显示两组IMR无显著差异(替格瑞洛21 U vs 普拉格雷18 U,P=0.08),替格瑞洛组心肌内出血发生率较低(23% vs 43%,P=0.04),但1个月梗死面积无差异。

要点

  • 替格瑞洛与普拉格雷维持治疗在改善STEMI患者冠脉微血管损伤方面无显著差异。
  • 替格瑞洛组心肌内出血发生率显著低于普拉格雷组(23% vs 43%,P=0.04)。
  • 两组1个月梗死面积和微血管阻塞发生率无显著差异。

核心结论

  • 在STEMI患者中,替格瑞洛维持治疗在预防梗死相关区域冠脉微血管损伤方面不优于普拉格雷,且1个月梗死面积相当。

研究设计与样本

  • 随机对照试验,共纳入110例接受直接PCI的STEMI患者,随机分为替格瑞洛维持治疗组(n=56)和普拉格雷维持治疗组(n=54)。

主要发现

  • 主要终点IMR在替格瑞洛组为21(IQR 15-39)U,普拉格雷组为18(IQR 11-29)U,P=0.08。
  • 微循环阻力随时间恢复程度两组无差异(替格瑞洛-13.9 U vs 普拉格雷-13.5 U,P=0.96)。
  • 心肌内出血发生率替格瑞洛组23%,普拉格雷组43%,P=0.04。
  • 1个月梗死面积替格瑞洛组7.6(IQR 3.7-14.4)g,普拉格雷组9.9(IQR 5.7-16.6)g,P=0.17。
  • 微血管阻塞发生率替格瑞洛组28%,普拉格雷组41%,P=0.35。

临床怎么用

  • 对于接受直接PCI的STEMI患者,替格瑞洛与普拉格雷维持治疗在改善微血管损伤方面效果相当,选择时可综合考虑其他临床因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite successful restoration of epicardial vessel patency with primary percutaneous coronary intervention, coronary microvascular injury occurs in a large proportion of patients with ST-segment-elevation myocardial infarction, adversely affecting clinical and functional outcome. Ticagrelor has been reported to increase plasma adenosine levels, which might have a protective effect on the microcirculation. We investigated whether ticagrelor maintenance therapy after revascularized ST-segment-elevation myocardial infarction is associated with less coronary microvascular injury compared to prasugrel maintenance therapy. METHODS: A total of 110 patients with ST-segment-elevation myocardial infarction received a loading dose of ticagrelor and were randomized to maintenance therapy of ticagrelor (n=56) or prasugrel (n=54) after primary percutaneous coronary intervention. The primary outcome was coronary microvascular injury at 1 month, as determined with the index of microcirculatory resistance in the infarct-related artery. Cardiovascular magnetic resonance imaging was performed during the acute phase and at 1 month. RESULTS: The primary outcome of index of microcirculatory resistance was not superior in ticagrelor- or prasugrel-treated patients (ticagrelor, 21 [interquartile range, 15-39] U; prasugrel, 18 [interquartile range, 11-29] U; P=0.08). Recovery of microcirculatory resistance over time was not better in patients with ticagrelor versus prasugrel (ticagrelor, -13.9 U; prasugrel, -13.5 U; P=0.96). Intramyocardial hemorrhage was observed less frequently in patients receiving ticagrelor (23% versus 43%; P=0.04). At 1 month, no difference in infarct size was observed (ticagrelor, 7.6 [interquartile range, 3.7-14.4] g, prasugrel 9.9 [interquartile range, 5.7-16.6] g; P=0.17). The occurrence of microvascular obstruction was not different in patients on ticagrelor (28%) or prasugrel (41%; P=0.35). Plasma adenosine concentrations were not different during the index procedure and during maintenance therapy with ticagrelor or prasugrel. CONCLUSIONS: In patients with ST-segment-elevation myocardial infarction, ticagrelor maintenance therapy was not superior to prasugrel in preventing coronary microvascular injury in the infarct-related territory as assessed by the index of microcirculatory resistance, and this resulted in a comparable infarct size at 1 month. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02422888.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. van Leeuwen MAH, van der Hoeven NW, Janssens GN, et al. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel. Circulation. 2019. PMID: 30586720. doi:10.1161/CIRCULATIONAHA.118.035931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。